Journal
JOURNAL OF MEDICINAL CHEMISTRY
Volume 55, Issue 12, Pages 5851-5858Publisher
AMER CHEMICAL SOC
DOI: 10.1021/jm3002795
Keywords
-
Categories
Funding
- Medicines for Malaria Venture
- Australian Research Council [FT0991213, LE0668477, LE0237908]
- Australian Research Council [LE0237908, LE0668477, FT0991213] Funding Source: Australian Research Council
Ask authors/readers for more resources
A new bispyrroloiminoquinone alkaloid, tsitsikammamine C (1), displayed potent in vitro antimalarial activity with IC50 values of 13 and 18 nM against chloroquine-sensitive (3D7) and chloroquine-resistant (Dd2) Plasmodium falciparum, respectively. Tsitsikammamine C (1) displayed selectivity indices of >200 against HEK293 cells and inhibited both ring and trophozoite stages of the malaria parasite life cycle. Previously reported compounds makaluvamines J (2), G (3), L (4), K (5) and damirones A (6) and B (7) were also isolated from the same marine sponge (Zyzzya sp.). Compounds 2-4 displayed potent growth inhibitory activity (IC50 < 100 nM) against both P. falciparum lines and only moderate c-ytotoxicity against HEK293 cells (IC50 = 1-4 mu M). Makaluvamine G (3) was not toxic to mice and suppressed parasite growth in P. berghei infected mice following subcutaneous administration at 8 mg kg(-1) day(-1).
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available